08:00 , Mar 10, 2003 |  BioCentury  |  Finance

Ebb & Flow

For those who think an M&A announcement represents the endgame for a biotech company, last week's maneuverings surrounding the proposed takeouts of Corvas (CVAS) and Oxford GlycoSciences (LSE:OGS; OGSI) provides notice that a deal may...
07:00 , Oct 14, 2002 |  BioCentury  |  Product Development

Celera not inhibited by triptases

The triptase inhibition program of Bayer AG and the former Axys Pharmaceuticals Inc. has run into multiple problems with formulation and toxicology since it was started in 1994. But Celera Genomics Group, which acquired Axys...
07:00 , Jul 24, 2000 |  BioCentury  |  Finance

Restarting the IPO engine

The industry priced $540.6 million of IPO paper last week, helped by the rebound in the sector and solid earnings from the big cap companies. While last month's proclamation of the mapping of the human...
07:00 , Aug 23, 1999 |  BioCentury  |  Finance

Divided we stand

Industry watchers have wondered for some time what the Monday partner meetings are like at venture firms that invest in both internet plays and biotechnology, given the different recent experiences of both. Institutional Venture Partners...
07:00 , Aug 2, 1999 |  BioCentury  |  Strategy

Axys: Selective disacquisition

Axys Pharmaceuticals Inc. - then Arris Pharmaceutical Corp. - acquired toolkit company Sequana Therapeutics Inc. in 1997 for $166 million in stock, a price many investors at the time fretted was too high (see BioCentury...
08:00 , Jan 25, 1999 |  BC Week In Review  |  Company News

Systems Integration Drug Discovery Co. Inc. board of directors update

Systems Integration Drug Discovery Co. Inc., Tucson, Ariz.   Business: Drug discovery   Appointed: Heinz Gschwend, formerly EVP at Arris Pharmaceutical Corp. , who also will serve as a consultant to SIDDCO  ...
07:00 , Apr 6, 1998 |  BC Week In Review  |  Company News

Axys drug discovery news

AXPH announced organizational changes resulting from the integration of Arris Pharmaceutical Corp. and Sequana Therapeutics Inc. , which merged last November to form AXPH. The company expects to realize $3-$5 million in annual savings in...
08:00 , Feb 9, 1998 |  BC Week In Review  |  Company News

Chiron, Pharmacia & Upjohn deal

The companies will identify small molecule inhibitors of the hepatitis C virus. The deal will combine CHIR’s HCV virology, protein expression, high throughput assay development and combinatorial chemistry capabilities with P&U’s structural biology, medicinal chemistry...
08:00 , Jan 19, 1998 |  BC Week In Review  |  Company News

Axys management update

(AXPH establishes division, B8) AxyS Pharmaceuticals Inc. (AXPH), South San Francisco, Calif.   Business: Drug discovery, Autoimmune/Inflammation   Hired: Michael Venuti as SVP of research, drug discovery, formerly VP of research and chief technical officer...
08:00 , Jan 19, 1998 |  BC Week In Review  |  Company News

Axys drug discovery news

AXPH established an Advanced Technologies Division that will include the company's combinatorial chemistry and pharmacogenomics technologies, as well as its Delta protease structure-based drug design technology. The division will include an ongoing combinatorial chemistry collaboration...